Crucial Moment In EU For Sanofi/GSK’s COVID-19 Vaccine, Amicus’s AAT-GAA & Y-mAbs’ Omburtamab

Vidprevtyn, from Sanofi/GSK, and drugs from Amicus and Y-mAbs are nearing the end of the European Medicines Agency review cycle. They are among the products scheduled for discussion this week by the CHMP, the EMA committee that decides whether drugs should be granted pan-EU approval.